ArticleLung cancer (Amsterdam, Netherlands)2021
Loss of wild type KRAS in KRAS
Article in Lung cancer (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Driver Gene Mutations Reprogram Lipid Metabolism in Non-Small Cell Lung Cancer.Cancer medicine · 2026Review
- Expression of LIFR in tumor and SHOC2, YAP1 in plasma mRNA as potential biomarkers in KRASScientific reports · 2026Article
- Fatty acid metabolic reprogramming in the tumor microenvironment: Unraveling mechanisms and therapeutic prospects.Genes & diseases · 2026Review
- Targeted metabolism creates possibilities for lung cancer treatment in the precision tumor era.Respiratory research · 2026Review
- Targeting cancer metabolism: Therapeutic potential of the fatty acid synthase (FASN) inhibitors.Critical reviews in oncology/hematology · 2025Review
- KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.Cell communication and signaling : CCS · 2024Article
- Emerging targets in lipid metabolism for cancer therapy.Trends in pharmacological sciences · 2024Review
- Unraveling the intricate relationship between lipid metabolism and oncogenic signaling pathways.Frontiers in cell and developmental biology · 2024Review
- Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics.Journal of hematology & oncology · 2023Review
- Anlotinib suppresses lung adenocarcinoma growth via inhibiting FASN-mediated lipid metabolism.Annals of translational medicine · 2022Article
- Overexpressed transient receptor potential vanilloid 1 (TRPV1) in lung adenocarcinoma harbours a new opportunity for therapeutic targeting.Cancer gene therapy · 2022Article
- Article
- Low CFB expression is independently associated with poor overall and disease-free survival in patients with lung adenocarcinoma.Oncology letters · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesWild type RAS (RAS MATERIALS AND
methodsWe evaluated for associations between LAKR and cancer mortality in patients with KRAS
results24 % of patients with KRAS
conclusionsLAKR in KRAS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.